Zydus Life receives final USFDA approval for insomnia drug

The approval granted by the US Food and Drug Administration (USFDA) is to market Triazolam tablets of strengths 0.125 mg and 0.25 mg, the company said in a regulatory filing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9KwmXPN
via IFTTT